Dihydroartemisinin/piperaquine: A review of its use in the treatment of uncomplicated plasmodium falciparum malaria

Drugs

Volumn 72, Issue 7, 2012, Pages 937-961

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Artemetherlumefantrine; Artesunatemefloquine; Dihydroartemisininpiperaquine; Falciparum malaria; Pharmacology

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; HALOTHANE; ISOFLURANE; NEFAZODONE; OMEPRAZOLE; PARACETAMOL; PIPERAQUINE; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; THEOPHYLLINE; VERAPAMIL;

ANTIMALARIAL ACTIVITY; CLINICAL TRIAL (TOPIC); DATA BASE; DERMATITIS; DIZZINESS; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG INTERACTION; DRUG METABOLISM; DRUG RESISTANCE; EMBASE; FEVER; GAMETOCYTE; HUMAN; IC 50; MALARIA; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; NAUSEA; NEUTROPENIA; NONHUMAN; PARASITEMIA; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; PUBLICATION; PUBLISHING; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REGISTER; REVIEW; SIDE EFFECT; STANDARD; STATISTICAL ANALYSIS; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

ARTESUNATE; PLASMODIUM FALCIPARUM;

EID: 84860722723     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203910-000000000-00000     Document Type: Review

References (79)

1. World Health Organization. Guidelines for the treatment of malaria: second edition [online]. Available from URL: http://whqlibdoc.who.int/ publications/2010/9789241547925-eng.pdf [Accessed 2012 Jan 12]
2. German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008; 47 (2): 91-102
3. World Health Organization. World malaria report 2011 [online]. Available from URL: http://www.who.int/malar ia/world-malaria-report-2011/WMR2011- noprofiles-lowres. pdf [Accessed 2012 Feb 14]
4. Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010 Apr; 8 (4): 272-80
5. European Medicines Agency. Eurartesim (dihydroartemisinin/piperaquine phosphate): EU public assessment report [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/001199/WC500118116.pdf [Accessed 2012 Jan 10]
6. Mayxay M, Keomany S, Khanthavong M, et al. A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin- piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. Am J Trop Med Hyg 2010; 83 (6): 1221-9
7. European Medicines Agency. Eurartesim (dihydroartemisinin/piperaquine) 20 mg/160 mg and 40 mg/320 mg film-coated tablets: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/hu man/001199/WC500118113.pdf [Accessed 2012 Jan 10]
8. Li W, Mo W, Shen D, et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet 2005 Sep; 1 (3): e36
9. Eckstein-Ludwig U, Webb RJ, van Goethem IDA, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003 Aug 21; 424 (6951): 957-61
10. Davis TME, Hung T-Y, Sim I-K, et al. Piperaquine: a resurgent antimalarial drug. Drugs 2005; 65 (1): 75-87
11. Nsobya SL, Kiggundu M, Nanyunja S, et al. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 2010 Mar; 54 (3): 1200-6
12. Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 2011 Nov; 6 (11): e26005
13. Briolant S, Henry M, Oeuvray C, et al. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother 2010 Sep; 54 (9): 3537-44
14. Muangnoicharoen S, Johnson DJ, Looareesuwan S, et al. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother 2009 Apr; 53 (4): 1362-6
15. Mwai L, Kiara SM, Abdirahman A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009 Dec; 53 (12): 5069-73
16. Gargano N, Cenci F, Bassat Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Trop Med Int Health 2011 Dec; 16 (12): 1466-73
17. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009 Jul 30; 361 (5): 455-67
18. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisininresistant malaria in western Cambodia [letter]. N Engl J Med 2008 Dec 11; 359 (24): 2619-20
19. Jambou R, Legrand E, Niang M, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005 Dec 3; 366 (9501): 1960-3
20. Basco LK, Ringwald P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1391-4
21. Somé AF, Séré YY, Dokomajilar C, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisininpiperaquine in Burkina Faso. Antimicrob Agents Chemother 2010May; 54 (5): 1949-54
22. Fivelman QL, Adagu IS, Warhurst DC. Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 2007 Jun; 51 (6): 2265-7
23. Davis TME, Hamzah J, Ilett KF, et al. In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2883-5
24. Valecha N, Phyo AP, Mayxay M, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 2010 Jul; 5 (7): e11880
25. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisininpiperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009 Nov 17; 4 (11): e7871
26. Mytton OT, Ashley EA, Peto L, et al. Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 2007 Sep; 77 (3): 447-50
27. Karunajeewa H, Lim C, Hung T-Y, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004 Jan; 57 (1): 93-9
28. Ashley EA, Krudsood S, Phaiphun L, et al. Randomized, controlled dose-optimization studies of dihydroartemisininpiperaquine for the treatment of uncomplicated multidrugresistant falciparum malaria in Thailand. J Infect Dis 2004 Nov 15; 190 (10): 1773-82
29. Ashley EA, McGready R, Hutagalung R, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 2005 Aug 15; 41 (4): 425-32
30. Borsini F, Crumb W, Pace S, et al. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination: comparison with other antimalarials. Antimicrob Agents Chemother. Epub 2012 Mar 5
31. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007 Aug; 7 (8): 549-58
32. Nguyen DVH, Nguyen QP, Nguyen ND, et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother 2009 Aug; 53 (8): 3534-7
33. Annerberg A, Lwin KM, Lindegardh N, et al. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother 2011 Sep; 55 (9): 3971-6
34. Sim I-K, Davis TME, Ilett KF. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2407-11
35. Chinh NT, Quang NN, Thanh NX, et al. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am J Trop Med Hyg 2008 Oct; 79 (4): 620-3
36. Hai TN, Hietala SF, Van Huong N, et al. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop 2008 Aug; 107 (2): 145-9
37. Hung TY, Davis TME, Ilett KF. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chrom B Anal Tech Biomed Life Sci 2003 Jul 5; 791 (1-2): 93-101
38. Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin- piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008 Mar; 52 (3): 1052-61
39. Tarning J, Lindegardh N, Sandberg S, et al. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J Pharm Sci 2008 Aug; 97 (8): 3400-10
40. Grande T, Bernasconi A, Erhart A, et al. A randomised controlled trial to assess the efficacy of dihydroartemisininpiperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One 2007 Oct; 2 (10): e1101
41. Hien TT, Dolecek C, Mai PP, et al. Dihydroartemisininpiperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004 Jan 3; 363 (9402): 18-22
42. Janssens B, van Herp M, Goubert L, et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2007 Feb; 12 (2): 251-9
43. Mayxay M, Thongpraseuth V, Khanthavong M, et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Trop Med Int Health 2006 Aug; 11 (8): 1157-65
44. Tangpukdee N, Krudsood S, Thanachartwet W, et al. An open randomized clinical trial of Artekin vs artesunatemefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005 Sep; 36 (5): 1085-91
45. Nambozi M, van Gerrtruyden J-P, Hachizovu S, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011 Feb 28; 10: 50
46. The 4ABC Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011 Nov; 8 (11): e1001119
47. Mens PF, Sawa P, van Amsterdam SM, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 2008 Nov 18; 7: 237
48. Adam I, Salah MT, Eltahir HG, et al. Dihydroartemisininpiperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol 2010; 104 (4): 319-26
49. Kamya MR, Yeka A, Bukirwa H, et al. Artemetherlumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007 May; 2 (5): e20
50. Yavo W, Faye B, Kuete T, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisininpiperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malaria J 2011 Jul 20; 10: 198
51. Yeka A, Dorsey G, Kamya MR, et al. Artemetherlumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008 Jun; 3 (6): e2390
52. Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007 Dec 1; 45 (11): 1453-61
53. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemetherlumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49 (11): 1629-37
54. Song J, Socheat D, Tan B, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malaria J 2011 Aug 10; 10: 231
55. Karema C, Fanello CI, Van Overmeir C, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006 Dec; 100 (12): 1105-11
56. Thanh NX, Trung TN, Phong NC, et al. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Health 2009 May; 14 (5): 504-511
57. Trung TN, Tan B, Van Phuc D, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisininpiperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med 2009 Jun; 15 (3): 189-92
58. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009 Feb; 4 (2): e4551
59. Rogers WO, Sem R, Tero T, et al. Failure of artesunatemefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 2009 Jan 12; 8: 10
60. Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008 Dec 11; 359 (24): 2545-57
61. Tarning J, Zongo I, Somé FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012 Mar; 91 (3): 497-505
62. Novartis Pharmaceuticals UK Ltd. Riamet (artemether/lumefantrine) 20 mg/120 mg tablets: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/9196/SPC/Riamet+ 20+120 mg+tablets/[Accessed 2012 Feb 14]
63. Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010 Jun; 10 (6): 405-16
64. Myint HY, Ashley EA, Day NP, et al. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007 Sep; 101 (9): 858-66
65. Zwang J, Ashley EA, Karema C, et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009 Jul; 4 (7): e6358
66. World Health Organization. International travel and health 2011 [online]. Available from URL: http://www.who.int/ith/en/[Accessed 2012 Jan 18]
67. Antinori S, Cigardi B, Galimberti L, et al. Diagnosis and therapy for hospitalized imported malaria in adults in Italy. J Travel Med 2011; 18 (6): 379-85
68. Kelesidis T, Kelesidis I, Rafailidis PI, et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007 Aug; 60 (2): 214-36
69. World Health Organization. Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa [online]. Available from URL: http://www.who.int/medicines/publications/WHO-QAMSA-report. pdf [Accessed 2012 Mar 19]
70. Nankabirwa J, Cundill B, Clarke S, et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One 2010 Oct; 5 (10): e13438
71. Cisse B, Cairns M, Faye E, et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 2009 Sep; 4 (9): e7164
72. Bojang K, Akor F, Bittaye O, et al. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One 2010 Jun; 5 (6): e11225
73. Lwin KM, Phyo AP, Tarning J, et al. A randomised, doubleblind, placebo controlled trial of monthly versus second monthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 2012 Mar; 56 (3): 1571-7
74. Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisininpiperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011 Nov 15; 53 (10): 977-84
75. Awab GR, Pukrittayakamee S, Imwong M, et al. Dihydroartemisinin- piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, noninferiority, trial. Malaria J 2010 Apr 21; 9: 105
76. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008 May 1; 46 (9): 1374-81
77. Rijken MJ, McGready R, Boel ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrugresistant Plasmodium falciparum malaria in pregnancy: a preliminary report. AmJ TropMedHyg 2008; 78 (4): 543-5
78. Rijken MJ, McGready R, Phyo AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2011 Dec; 55 (12): 5500-6
79. Tarning J, Rijken MJ, McGready R, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated malaria. Antimicrob Agents Chemother 2012 Apr; 56 (4): 1997-2007